| Title |
Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial
|
|---|---|
| Published in |
Supportive Care in Cancer, December 2017
|
| DOI | 10.1007/s00520-017-4013-0 |
| Pubmed ID | |
| Authors |
Ian R. Kleckner, Charles Kamen, Jennifer S. Gewandter, Nimish A. Mohile, Charles E. Heckler, Eva Culakova, Chunkit Fung, Michelle C. Janelsins, Matthew Asare, Po-Ju Lin, Pavan S. Reddy, Jeffrey Giguere, Jeffrey Berenberg, Shelli R. Kesler, Karen M. Mustian |
| Abstract |
Over half of all cancer patients receiving taxane-, platinum-, or vinca alkaloid-based chemotherapy experience chemotherapy-induced peripheral neuropathy (CIPN), which includes numbness, tingling, pain, cold sensitivity, and motor impairment in the hands and feet. CIPN is a dose-limiting toxicity, potentially increasing mortality. There are no FDA-approved drugs to treat CIPN, and behavioral interventions such as exercise are promising yet understudied. This secondary analysis of our nationwide phase III randomized controlled trial of exercise for fatigue examines (1) effects of exercise on CIPN symptoms, (2) factors that predict CIPN symptoms, and (3) factors that moderate effects of exercise on CIPN symptoms. Cancer patients (N = 355, 56 ± 11 years, 93% female, 79% breast cancer) receiving taxane-, platinum-, or vinca alkaloid-based chemotherapy were randomized to chemotherapy or chemotherapy plus Exercise for Cancer Patients (EXCAP©®). EXCAP is a standardized, individualized, moderate-intensity, home-based, six-week progressive walking and resistance exercise program. Patients reported CIPN symptoms of numbness and tingling and hot/coldness in hands/feet (0-10 scales) pre- and post-intervention. We explored baseline neuropathy, sex, age, body mass index, cancer stage, and cancer type as possible factors associated with CIPN symptoms and exercise effectiveness. Exercise reduced CIPN symptoms of hot/coldness in hands/feet (-0.46 units, p = 0.045) and numbness and tingling (- 0.42 units, p = 0.061) compared to the control. Exercise reduced CIPN symptoms more for patients who were older (p = 0.086), male (p = 0.028), or had breast cancer (p = 0.076). Exercise appears to reduce CIPN symptoms in patients receiving taxane-, platinum-, or vinca alkaloid-based chemotherapy. Clinicians should consider prescribing exercise for these patients. Clinical Trials.gov , # NCT00924651, http://www.clinicaltrials.gov . |
X Demographics
The data shown below were collected from the profiles of 199 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 37 | 19% |
| United Kingdom | 27 | 14% |
| Australia | 18 | 9% |
| Canada | 6 | 3% |
| Spain | 6 | 3% |
| Brazil | 6 | 3% |
| New Zealand | 2 | 1% |
| Greece | 2 | 1% |
| Sweden | 2 | 1% |
| Other | 21 | 11% |
| Unknown | 72 | 36% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 111 | 56% |
| Scientists | 55 | 28% |
| Practitioners (doctors, other healthcare professionals) | 32 | 16% |
| Science communicators (journalists, bloggers, editors) | 1 | <1% |
Mendeley readers
The data shown below were compiled from readership statistics for 425 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 425 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 56 | 13% |
| Student > Bachelor | 51 | 12% |
| Researcher | 35 | 8% |
| Student > Ph. D. Student | 27 | 6% |
| Student > Doctoral Student | 23 | 5% |
| Other | 95 | 22% |
| Unknown | 138 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Nursing and Health Professions | 88 | 21% |
| Medicine and Dentistry | 78 | 18% |
| Sports and Recreations | 26 | 6% |
| Neuroscience | 17 | 4% |
| Unspecified | 14 | 3% |
| Other | 40 | 9% |
| Unknown | 162 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 137. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 March 2024.
All research outputs
#309,744
of 25,782,229 outputs
Outputs from Supportive Care in Cancer
#10
of 5,128 outputs
Outputs of similar age
#6,771
of 446,200 outputs
Outputs of similar age from Supportive Care in Cancer
#1
of 86 outputs
Altmetric has tracked 25,782,229 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,128 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 446,200 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 86 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.